Melanoma vaccines: clinical status and immune endpoints
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-04-01 / Melanoma Res. 2019 04;29(2):109-118New treatment modalities with vaccine therapy in renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2019-04-01 / Urol Ann 2019 Apr-Jun;11(2):119-125Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2019-04-01 / Anticancer Res 2019 Apr;39(4):2043-2051A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2019-04-01 / Stem Cells Int 2019;2019:5680327[Vaccines for the treatment of non-small cell lung cancer]
/in Dendritic Cells, International Publications, NSCLC /von 2019-03-20 / Rev Mal Respir 2019 Mar;36(3):415-425Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-03-05 / Cancers (Basel) 2019 Mar;11(3)Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine
/in Acute Leukemia, Dendritic Cells, International Publications /von 2019-03-03 / Br. J. Haematol. 2019 May;185(4):679-690Randomized phase II trial of patient-specific dendritic cell vaccines loaded with autologous tumor antigens versus autologous monocytes in patients with primary advanced ovarian cancer.
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-03-01 / J Clin Oncol 37, 2019 (suppl 8; abstr TPS10)Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma
/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2019-02-27 / Clin Colorectal Cancer 2019 Jun;18(2):81-90
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de